Recent News

• 09.16.2025 - HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
• 09.16.2025 - HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
• 09.09.2025 - HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
• 09.09.2025 - HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
• 08.25.2025 - HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
• 08.25.2025 - HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
• 08.18.2025 - HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
• 08.18.2025 - HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
• 06.27.2025 - HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
• 06.27.2025 - HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Recent Filings

• 09.05.2025 - 8-K Current report
• 08.19.2025 - 8-K Current report
• 08.18.2025 - 8-K/A Current report
• 08.18.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.15.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 08.15.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 07.18.2025 - 8-K Current report
• 07.01.2025 - 8-K Current report